RxDoctor Payments Data

Surjit Athwal Johal, MD

Internal Medicine · Coconut Creek, FLNPI 1679586044

Payments from drug & device makers

$6,198in general payments, 2019–2025

Across 237 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$942
  • Johnson & Johnson$743
  • Pfizer$470
  • Lilly USA, LLC$429
  • GSK$396
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,193100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,198 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,602
Medicare patients
27
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$29,356
JardianceEmpagliflozin15$21,014
MounjaroTirzepatide19$19,495
JanuviaSitagliptin Phosphate16$12,132
FarxigaDapagliflozin Propanediol17$11,821
Atorvastatin Calcium116$836
Levothyroxine Sodium42$736
Tamsulosin Hcl49$643
Omeprazole65$473
Losartan Potassium58$469
Rosuvastatin Calcium26$439
Metoprolol Succinate32$438
Chlorthalidone21$357
Amlodipine Besylate72$330
Nifedipine ErNifedipine11$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$942$29,35630 claims
Boehringer IngelheimJardiance$352$21,01415 claims
Lilly USA, LLCMounjaro$429$19,49519 claims
MerckJanuvia$284$12,13216 claims
AstraZenecaFarxiga$1,350$11,82117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Coconut Creek

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →